Potential Uses of Hemoglobin-based Oxygen Carriers in Critical Care Medicine
Potential Uses of Hemoglobin-based Oxygen Carriers in Critical Care Medicine
复制标题
DOI：
10.1016/j.ccc.2008.12.011
复制
发表时间：
2009-04-01
影响因子：
4.3
通讯作者：
Vincent, Jean-Louis
中科院分区：
文献类型：
--
作者：
Creteur, Jacques;Vincent, Jean-Louis
血红蛋白氧载体（HBOCs）最初是为了提供输血的替代品而开发的。随着认识到血红蛋白溶液不仅是红细胞替代品，而且还具有许多额外的特性，包括与其抗氧化剂和一氧化氮清除作用相关的血液动力学效应，更广泛的“血红蛋白治疗”概念诞生了。对氧转运和微循环的有希望的作用需要得到证实，人们迫切期待着更新的第二代HBOCs的研究结果。与此同时，在HBOC广泛用于ICU、急诊室或院前环境之前，需要仔细评估可能的不良反应。
Hemoglobin-based oxygen carriers (HBOCs) were initially developed to provide an alternative to blood transfusion. With the realization that hemoglobin solutions not only are red blood cell substitutes but also have a number of additional properties, including hemodynamic effects related to their oncotic and nitric oxide-scavenging effects, the broader concept of "hemoglobin therapeutics" was born. Promising effects on oxygen transport and the microcirculation need to be confirmed, and the results of studies with newer, second-generation HBOCs are eagerly awaited. In the meantime, possible adverse effects need to be carefully evaluated before HBOCs can be widely used in the ICU, emergency room, or prehospital setting.